- call +1-201-465-4211
- email sales@mrinsights.biz
Cardiovascular disease (CVD) is a major cause of death in the U.S. and rest of the world. These diseases are primarily related with heart and blood vessels disorders, such asischemic heart disease, dyslipidemia, stroke, thrombosis, atherosclerosis, coronary artery diseases, peripheral artery disease and others. These disorders are mainly reported due to obesity, high cholesterol, smoking, excessi alcohol, and poor lifestyle.
Scope of the Report:
This report focuses on the Cardiovascular Drug in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The hypertension segment recorded $64.9 billion in sales in 2009. By a large margin, hypertension is the largest segment within the cardiovascular market, driven by a large number of billion-dollar-plus therapies.
The worldwide market for Cardiovascular Drug is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new study.
Market Segment by Manufacturers, this report covers
Amgen
AstraZeneca
Bayer
Bristol Myers Squibb and Pfizer
Daiichi Sankyo
Johnson & Johnson
Merck & Co.
Novartis
Pfizer
Portola
Sanofi
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
heparin
Coumadin
Sectral
Zebeta
Lopressor
Toprol XL
Norvasc
Lotrel
Market Segment by Applications, can be divided into
Hospital
Clinic
Others
There are 15 Chapters to deeply display the global Cardiovascular Drug market.
Chapter 1, to describe Cardiovascular Drug Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Cardiovascular Drug, with sales, revenue, and price of Cardiovascular Drug, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Cardiovascular Drug, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Cardiovascular Drug market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Cardiovascular Drug sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Cardiovascular Drug Introduction
1.2 Market Analysis by Type
1.2.1 heparin
1.2.2 Coumadin
1.2.3 Sectral
1.2.4 Zebeta
1.2.5 Lopressor
1.2.6 Toprol XL
1.2.7 Norvasc
1.2.8 Lotrel
1.3 Market Analysis by Applications
1.3.1 Hospital
1.3.2 Clinic
1.3.3 Others
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Amgen
2.1.1 Business Overview
2.1.2 Cardiovascular Drug Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Amgen Cardiovascular Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 AstraZeneca
2.2.1 Business Overview
2.2.2 Cardiovascular Drug Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 AstraZeneca Cardiovascular Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Bayer
2.3.1 Business Overview
2.3.2 Cardiovascular Drug Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Bayer Cardiovascular Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Bristol Myers Squibb and Pfizer
2.4.1 Business Overview
2.4.2 Cardiovascular Drug Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Bristol Myers Squibb and Pfizer Cardiovascular Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Daiichi Sankyo
2.5.1 Business Overview
2.5.2 Cardiovascular Drug Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Daiichi Sankyo Cardiovascular Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Johnson & Johnson
2.6.1 Business Overview
2.6.2 Cardiovascular Drug Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Johnson & Johnson Cardiovascular Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Merck & Co.
2.7.1 Business Overview
2.7.2 Cardiovascular Drug Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Merck & Co. Cardiovascular Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Novartis
2.8.1 Business Overview
2.8.2 Cardiovascular Drug Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Novartis Cardiovascular Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Pfizer
2.9.1 Business Overview
2.9.2 Cardiovascular Drug Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Pfizer Cardiovascular Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Portola
2.10.1 Business Overview
2.10.2 Cardiovascular Drug Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Portola Cardiovascular Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.11 Sanofi
2.11.1 Business Overview
2.11.2 Cardiovascular Drug Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Sanofi Cardiovascular Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Cardiovascular Drug Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Cardiovascular Drug Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Cardiovascular Drug Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Cardiovascular Drug Manufacturer Market Share in 2017
3.3.2 Top 6 Cardiovascular Drug Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Cardiovascular Drug Market Analysis by Regions
4.1 Global Cardiovascular Drug Sales, Revenue and Market Share by Regions
4.1.1 Global Cardiovascular Drug Sales and Market Share by Regions (2013-2018)
4.1.2 Global Cardiovascular Drug Revenue and Market Share by Regions (2013-2018)
4.2 North America Cardiovascular Drug Sales and Growth Rate (2013-2018)
4.3 Europe Cardiovascular Drug Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Cardiovascular Drug Sales and Growth Rate (2013-2018)
4.5 South America Cardiovascular Drug Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Cardiovascular Drug Sales and Growth Rate (2013-2018)
5 North America Cardiovascular Drug by Countries
5.1 North America Cardiovascular Drug Sales, Revenue and Market Share by Countries
5.1.1 North America Cardiovascular Drug Sales and Market Share by Countries (2013-2018)
5.1.2 North America Cardiovascular Drug Revenue and Market Share by Countries (2013-2018)
5.2 United States Cardiovascular Drug Sales and Growth Rate (2013-2018)
5.3 Canada Cardiovascular Drug Sales and Growth Rate (2013-2018)
5.4 Mexico Cardiovascular Drug Sales and Growth Rate (2013-2018)
6 Europe Cardiovascular Drug by Countries
6.1 Europe Cardiovascular Drug Sales, Revenue and Market Share by Countries
6.1.1 Europe Cardiovascular Drug Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Cardiovascular Drug Revenue and Market Share by Countries (2013-2018)
6.2 Germany Cardiovascular Drug Sales and Growth Rate (2013-2018)
6.3 UK Cardiovascular Drug Sales and Growth Rate (2013-2018)
6.4 France Cardiovascular Drug Sales and Growth Rate (2013-2018)
6.5 Russia Cardiovascular Drug Sales and Growth Rate (2013-2018)
6.6 Italy Cardiovascular Drug Sales and Growth Rate (2013-2018)
7 Asia-Pacific Cardiovascular Drug by Countries
7.1 Asia-Pacific Cardiovascular Drug Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Cardiovascular Drug Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Cardiovascular Drug Revenue and Market Share by Countries (2013-2018)
7.2 China Cardiovascular Drug Sales and Growth Rate (2013-2018)
7.3 Japan Cardiovascular Drug Sales and Growth Rate (2013-2018)
7.4 Korea Cardiovascular Drug Sales and Growth Rate (2013-2018)
7.5 India Cardiovascular Drug Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Cardiovascular Drug Sales and Growth Rate (2013-2018)
8 South America Cardiovascular Drug by Countries
8.1 South America Cardiovascular Drug Sales, Revenue and Market Share by Countries
8.1.1 South America Cardiovascular Drug Sales and Market Share by Countries (2013-2018)
8.1.2 South America Cardiovascular Drug Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Cardiovascular Drug Sales and Growth Rate (2013-2018)
8.3 Argentina Cardiovascular Drug Sales and Growth Rate (2013-2018)
8.4 Colombia Cardiovascular Drug Sales and Growth Rate (2013-2018)
9 Middle East and Africa Cardiovascular Drug by Countries
9.1 Middle East and Africa Cardiovascular Drug Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Cardiovascular Drug Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Cardiovascular Drug Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Cardiovascular Drug Sales and Growth Rate (2013-2018)
9.3 UAE Cardiovascular Drug Sales and Growth Rate (2013-2018)
9.4 Egypt Cardiovascular Drug Sales and Growth Rate (2013-2018)
9.5 Nigeria Cardiovascular Drug Sales and Growth Rate (2013-2018)
9.6 South Africa Cardiovascular Drug Sales and Growth Rate (2013-2018)
10 Global Cardiovascular Drug Market Segment by Type
10.1 Global Cardiovascular Drug Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Cardiovascular Drug Sales and Market Share by Type (2013-2018)
10.1.2 Global Cardiovascular Drug Revenue and Market Share by Type (2013-2018)
10.2 heparin Sales Growth and Price
10.2.1 Global heparin Sales Growth (2013-2018)
10.2.2 Global heparin Price (2013-2018)
10.3 Coumadin Sales Growth and Price
10.3.1 Global Coumadin Sales Growth (2013-2018)
10.3.2 Global Coumadin Price (2013-2018)
10.4 Sectral Sales Growth and Price
10.4.1 Global Sectral Sales Growth (2013-2018)
10.4.2 Global Sectral Price (2013-2018)
10.5 Zebeta Sales Growth and Price
10.5.1 Global Zebeta Sales Growth (2013-2018)
10.5.2 Global Zebeta Price (2013-2018)
10.6 Lopressor Sales Growth and Price
10.6.1 Global Lopressor Sales Growth (2013-2018)
10.6.2 Global Lopressor Price (2013-2018)
10.7 Toprol XL Sales Growth and Price
10.7.1 Global Toprol XL Sales Growth (2013-2018)
10.7.2 Global Toprol XL Price (2013-2018)
10.8 Norvasc Sales Growth and Price
10.8.1 Global Norvasc Sales Growth (2013-2018)
10.8.2 Global Norvasc Price (2013-2018)
10.9 Lotrel Sales Growth and Price
10.9.1 Global Lotrel Sales Growth (2013-2018)
10.9.2 Global Lotrel Price (2013-2018)
11 Global Cardiovascular Drug Market Segment by Application
11.1 Global Cardiovascular Drug Sales Market Share by Application (2013-2018)
11.2 Hospital Sales Growth (2013-2018)
11.3 Clinic Sales Growth (2013-2018)
11.4 Others Sales Growth (2013-2018)
12 Cardiovascular Drug Market Forecast (2018-2023)
12.1 Global Cardiovascular Drug Sales, Revenue and Growth Rate (2018-2023)
12.2 Cardiovascular Drug Market Forecast by Regions (2018-2023)
12.2.1 North America Cardiovascular Drug Market Forecast (2018-2023)
12.2.2 Europe Cardiovascular Drug Market Forecast (2018-2023)
12.2.3 Asia-Pacific Cardiovascular Drug Market Forecast (2018-2023)
12.2.4 South America Cardiovascular Drug Market Forecast (2018-2023)
12.2.5 Middle East and Africa Cardiovascular Drug Market Forecast (2018-2023)
12.3 Cardiovascular Drug Market Forecast by Type (2018-2023)
12.3.1 Global Cardiovascular Drug Sales Forecast by Type (2018-2023)
12.3.2 Global Cardiovascular Drug Market Share Forecast by Type (2018-2023)
12.4 Cardiovascular Drug Market Forecast by Application (2018-2023)
12.4.1 Global Cardiovascular Drug Sales Forecast by Application (2018-2023)
12.4.2 Global Cardiovascular Drug Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Cardiovascular Drug Picture
Table Product Specifications of Cardiovascular Drug
Figure Global Sales Market Share of Cardiovascular Drug by Types in 2017
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
